Global Preimplantation Genetic Testing Market Overview
The key driver impacting the preimplantation genetic testing market is the rising incidence of gene-related disorders creating demand for preimplantation diagnosis and screening processes. For instance, As per NCBI, Sickle cell disease (SCD) is one of the most common genetic hematological disorders. It accounts for 305000 births in 2010, with millions of people affected globally in 2018. The Center for Disease Control and Prevention (CDC) reports that Sickle Cell Disease affects over 100,000 Americans. Around one in every 365 African-American babies is born with Sickle Cell Disease in the U.S., Whereas one in every 16,300 Hispanic-American babies is diagnosed with sickle cell disease. The other most common genetic disorder is Cystic Fibrosis. As per the Cystic Fibrosis Foundation, More than 30,000 people are living with cystic fibrosis in the United States, more than 70,000 globally, and approximately 1,000 new CF cases are diagnosed each year. Moreover, growing technological advancements have enhanced the accuracy of prenatal screening and early detection of chromosomal abnormalities in an embryo, with affordable testing, contributing to market growth.
According to Value Market Research, the global preimplantation genetic testing market size was valued at around USD 500 Million by 2020 and is estimated to grow at a CAGR of about 10% during the forecast period 2021 to 2027.
The growing number of supportive initiatives adopted by the government authorities to promote reproductive health and approval for preimplantation genetic testing is estimated to augment preimplantation genetic testing demand in the forecast period. For instance, in June 2017, the Switzerland government had given the approval of the pre-implantation genetic diagnosis of an in-vitro embryo. In the U.S. The American Society for Reproductive Medicine (ASRM) also allowed the usage of PGD for preventing sex-linked diseases is ethical. However, the high costs associated with preimplantation genetic testing may hamper the global preimplantation genetic testing market in the long run. Also, the unfavorable government regulations negatively impact the market. The current industry trends, such as the technological progression in the field of genetic analysis and the high risk of chromosomal abnormalities with increased maternal age, are expected to provide market players with new market opportunities.
The preimplantation genetic testing market is vast, with many local and global players. The preimplantation genetic testing market is extensive, with many local and international players. The key leaders follow numerous strategies to increase their market position, such as extending product portfolio, contracts, amalgamation, extending product portfolio, product advancement, and acquisitions to improve their market share across the globe. For instance, In October 2019, PerkinElmer introduced PG-Seq Rapid Non-Invasive Pre-implantation Genetic Testing Kit for Aneuploidy application (PGT-A). It is a non-invasive option to traditional IVF embryo biopsies. The significant players studied in the report are Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Good Start Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, California Pacific Medical Center, Quest Diagnostics Incorporated, Natera, Inc., Reproductive Health Science Ltd., CooperSurgical, Inc., Bioarray S.L., Genea Limited, Reproductive Genetic Innovations, LLC, IGENOMIX, CombiMatrix, and F. Hoffmann-La Roche AG.
In this research report, the preimplantation genetic testing market is segmented by product, procedure type, application, end-user, and region.
Analysis by Product:
By product, the report is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables dominate the product segment with a 40% share in 2020. The expanding application horizons of specific technologies (such as NGS and aCGH for whole-genome sequencing and FISH in diagnosing particular genetic disorders are majorly boosting the segment growth. Moreover, ease of use compared to conventional methods creates more demands for reagents & consumables segments in the forecast period.
Analysis by Procedure Type:
By procedure type, the report is segmented into preimplantation genetic screening(PGS) and preimplantation genetic diagnosis(PGD). The PGS dominate the procedure type segment with a 55% share in 2020. It is due to growing awareness about the screening of embryos for chromosomal abnormalities. It is best suited for couples with multiple IVF cycles, advanced reproductive age, and recurrent pregnancy loss. Moreover, many IVF processes are conducted in high-capacity laboratories due to the presence of better facilities, contributing to PGS technique segment growth in the forecast period.
Analysis by Application:
By application, the report is categorized into aneuploidy, structural chromosomal abnormalities, translocations, deletions, duplications, inversions, single-gene disorders, x-linked disorders, HLA typing, and gender identification. The aneuploidy application segment dominates the application segment with a 25% share in 2020. It is because aneuploidy screening during PGD has improved the IVF procedures that increase its demand. Moreover, the introduction of aneuploidy testing in IVF centers identifies abnormal embryos, resulting in successful pregnancy rates, contributing to the aneuploidy application segment's growth in the forecast period.
Analysis by End-User:
By end-user, the report is categorized into maternity centers & fertility clinics, hospitals, diagnostic labs, and service providers. The maternity centers & fertility clinics segment dominates the end-user segment with a 20% share in 2020. It is because IVF procedures and preimplantation genetic testing procedures are majorly conducted at fertility clinics and maternity centers. Moreover, growing awareness about assisted reproduction techniques and a growing number of fertility clinics worldwide contribute to the segment's growth in the forecast period.
Analysis by Region:
In the regional outlook of the global preimplantation genetic testing market, the North America region dominates with the most significant market share during the forecast period. It is due to the growing volume of chromosome abnormality cases leading to various genetic disorders. Also, the launch of new products by key players and a rise in healthcare infrastructure improvements in the United States generates more revenue. Moreover, the increase in government initiatives towards creating awareness among people and growing preference among couples for preimplantation genetic testing tests during IVF and other artificial insemination procedures contribute to the market's growth across North America.
Market Segmentation covered in the Report:
By Procedure Type
- Reagents & Consumables
- Software & Services
- Preimplantation Genetic Screening
- Preimplantation Genetic Diagnosis
By End User
- Structural Chromosomal Abnormalities
- Single Gene Disorders
- X-linked Disorders
- HLA Typing
- Gender Identification
- Maternity Centers & Fertility Clinics
- Hospitals, Diagnostic Labs, and Service Providers
- Research Laboratories & Academic Institutes
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.